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Abstract
Background. The effect of the specific endothelin A
(ETA)-receptor antagonist LU 302146 (LU) was
assessed in a normotensive model of chronic trans-
plant vasculopathy, i.e. orthotopic allotransplantation
of the infrarenal abdominal aorta from spontaneously
hypertensive-to-Wistar–Kyoto (SHR-to-WKY) rats.
A second experimental setting was used to confirm
the results in a different model, which to some extent
may also address the issue of blood pressure (BP) in
transplant vasculopathy, i.e. orthotopic allotrans-
plantation of infrarenal abdominal aorta from
WKY-to-SHR rats. Untreated sham-operated and
isografted WKY and SHR served as controls. Allo-
transplanted animals treated with the angiotensin-
converting enzyme (ACE) inhibitor trandolapril
served as positive treatment controls.
Methods. Rats were randomized to receive standard
diet or a diet designed to deliver either 30 mg LUukg
bwuday, 0.3 mgukg bwuday trandolapril or a combina-
tion of both. The duration of either experiment was
8 weeks. BP was measured by tail plethysmography.
Results. Treatment with LU did not affect systolic
BP in either experimental setting. In contrast, tran-
dolapril and combination treatment significantly
reduced systolic BP in SHRs. The increase in aortic
wall thickness (given in mm) was abrogated to a
similar extent in the three treatment groups as
compared with untreated allotransplanted animals in
either experimental setting (e.g. WKY sham-operated
0.084"0.013, P-0.05 vs treatment groups; WKY
isotransplanted 0.100"0.010, P-0.05 vs treatment
groups; WKY allotransplanted 0.289"0.077, P-0.05
vs all groups; WKY allotransplantedqtrandolapril
0.185"0.025; WKY allotransplantedqLU 301246
0.192"0.049; WKY allotransplantedqLU 301246q
trandolapril 0.190"0.041). This was due to an
attenuation of the increase of intima and media
thickness. Treatment with LU and trandolapril were
similarly effective in attenuating the increase of the
number of proliferating cell nuclear antigen (PCNA)-
positive cells in the intima. Again, combination
treatment did not confer additional benefit. In
contrast, trandolapril was more effective than LU in
attenuating the increase in the number of PCNA-
positive cells in the media. Trandolapril or combina-
tion treatment, but not LU, attenuated transforming
growth factor-b expression in aortic allografts.
Conclusions. The ETA-receptor blockade abrogates
allograft vasculopathy in two different aorta allo-
transplantation models to a similar extent as ACE
inhibition even in the absence of concomitant immuno-
suppression. At least in SHRs the effect of ETA-
receptor blockade is independent of BP. This finding
is consistent with the notion that ETA-receptor
mediated events play a partly BP-independent role in
the genesis of chronic transplant vasculopathy.
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Introduction
So-called ‘chronic rejection’ is the major cause of renal
and cardiac allograft loss, and no specific treatment of
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this entity is available. Although chronic rejection is
triggered by immune mechanisms, damage is perpe-
tuated and amplified by non-immune mechanisms,
potentially including the endothelin (ET) and renin–
angiotensin systems. Recent experimental studies have
shown that ET-1 gene expression anduor increased
synthesis of ET-1 are found during chronic rejection of
renal and cardiac allografts. Chronic rejection of rat
cardiac allografts is associated with increased ET-1
expression in ventricular tissue, which is particularly
pronounced in areas of intimal proliferation [1].
Expression of ET-1 is also seen in cardiac myofibers
that are situated in close proximity to areas of
interstitial inflammation or fibrosis [2]. The potential
clinical relevance of these findings is supported by an
increased expression of ET-1 in biopsy specimens of
humans with cardiac or renal allografts undergoing
chronic rejection [3,4].
We have recently reported that ETA-receptor block-
ade and angiotensin-converting enzyme (ACE) inhi-
bition are equally effective in attenuating the
development of chronic transplant nephropathy in a
‘Fisher-to-Lewis’ rat model [5]. Combination treat-
ment of both substances had no additive nephro-
protective effect. In contrast to ACE inhibition, the effect
of ETA-receptor blockade was independent of blood
pressure (BP). This finding is noteworthy, because BP
is apparently an important non-immune mechanism
promoting chronic rejection, at least of renal allo-
grafts [6]. Thus, ETA-receptor-mediated events seem
to be of pivotal, BP-independent importance in the
genesis of chronic allograft rejection. BP may, however,
modulate the beneficial effect of ETA-receptor blockade.
It is therefore crucial to investigate whether our
findings in a ‘Fisher-to-Lewis’ rat model [5] are specific
for kidney transplantation or can be generalized and
demonstrated for other organ transplants as well.
Thus, the effect of specific ETA-receptor blockade with
LU 302146 (LU) on the development of chronic
allograft vasculopathy was investigated in an ortho-
topic aorta allotransplantation model, i.e. trans-
plantation of infrarenal aorta from spontaneously
hypertensive-to-Wistar–Kyoto (SHR-to-WKY) rats.
As a control, ACE inhibition was assessed in parallel.
A parallel experiment was performed to confirm the
results in another chronic transplant vasculopathy
model that probably also addresses the issue of BP
in the genesis of transplant vasculopathy, i.e. a hyper-
tensive model of orthotopic allotransplantation of
infrarenal abdominal aorta from WKY-to-SHR rats.
Subjects and methods
Animals
Eight-week-old male SHR (ns72) and WKY (ns71) rats
weighing 180–200 g were purchased from M&B AuS (Ry,
Denmark) and Iffa-Credo (Lyon, France), respectively. The
rats were fed standard rat chow (0.25% NaCl and 19%
protein; ssnif GmbH, Soest, Germany).
Aorta transplantation and experimental design
Aortas were transplanted by microsurgical techniques under
anaesthesia with xylazine (5 mgukg body weight) and
ketamine (100 mgukg body weight). Using the operation
microscope, the infrarenal aorta was exposed from the left
renal vein to the aortic bifurcation via midline laparotomy.
Any aortic branches in this segment were ligated.
Two microclips were placed, one below the renal arteries
and the second above the aortic bifurcation. A 1 cm seg-
ment of the aorta was removed from the donor animal and
washed with saline solution. A similar resection of the
infrarenal aorta was performed in the recipient rat. The graft
was inserted into the aorta of the recipient by end-to-end
interrupted anastomoses, using 10-0 prolene sutures. The
aorta was clamped for 30 min; thereafter patency of each
graft was evaluated. No acute secondary graft thrombosis
was observed. Twelve SHRs and 11 WKY rats were
sham-operated, including ligature of collateral vessels.
Furthermore, 12 animals of either strain were isografted
as additional controls. The advantage of both models
investigated is that no immunosuppressive treatment is
necessary.
The WKY-to-SHR allografts and SHR-to-WKY allo-
grafts with no treatment were compared with WKY-to-SHR
and SHR-to-WKY allografts treated with LU, trandolapril
and a combination of both (each group ns12). LU 302146
was added to the food calculated to deliver 30 mgukg bwuday
and trandolapril to deliver 0.3 mgukg bwuday. This dose
of the ETA-receptor blocker was chosen because it is
known to completely block ETA-receptors without affecting
ETB-receptors [7]. LU 302146 is the follow-up molecule
of LU 135252 with similar pharmacological properties
(M. Raschack, personal communication). To allow com-
parability, the same dose of trandolapril was chosen as in
our experiment in the ‘Fisher-to-Lewis’ chronic transplant
nephropathy model [5]. Treatment was started on the
first day post-operation. A pair-feeding protocol was used
throughout the experiment. BP of awake rats was measured
weekly by tail plethysmography. Rats were sacrificed after
8 weeks and the infrarenal aortic graft (or native aorta in
sham-operated animals) was excised. The grafts were fixed in
formalin for morphometric analysis and immunohistochemi-
cal studies. A few animals died shortly after operation. The
final numbers of animals investigated in each group were:
nine in the WKY sham-operated group, 12 in the WKY
isograft group, 10 in the allotransplanted WKY group, and
11, 9 and 10 in the allotransplanted WKY animals treated
with trandolapril, LU 302146, or a combination of both, res-
pectively. There were 12 in all SHR groups, except 10 in the
allotransplanted SHR group and 10 in the allotransplanted
SHR treated with trandolapril groups.
Morphometric investigations
Cross sections of the aortic graft were prepared, semithin
(1 mm) sections were cut, stained with methylene blue and
basic fuchsin, and studied planimetrically as described below
at a magnification of 380. Using a semiautomatic image
analysing system (Optimas 5.2, Bioscan, Stemmer Co.,
Munich, Germany), the external and internal contours of
the media and intima were outlined, and the cross-sectional
area, wall thickness, and minimal and maximal lumen
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diameters calculated. The wall:lumen ratio was calculated by
dividing the mean wall diameter by the minimal lumen
diameter.
Connective tissue staining and immunohistochemistry
Staining for connective tissue was performed in formalin-
fixed, paraffin-embedded sections, which were stained with
Sirius. Immunohistochemistry was performed essentially as
described previously [8]. Paraffin-embedded sections were
deparaffinized with xylene and graded ethanols before being
treated with Power Block (Biogenex, Ramon, CA, USA) for
20 min to inhibit the non-specific staining. The sections were
incubated either with anti-proliferating cell nuclear anti-
gen (anti-PCNA) antibody (1:150 dilution; Immunotech,
Marseille, France) or anti-transforming growth factor-b
(anti-TGF-b) antibody (1:100 dilution; Santa Cruz Bio-
technology, Santa Cruz, CA, USA) at 48C overnight and
were subsequently processed using a biotin–streptavidin
detection system (biotin–streptavidin super sensitive; Biogenex)
with fast red substrate system (DAKO Diagnostika GmbH,
Hamburg, Germany) as the chromogen. The sections were
finally counterstained with haematoxylin. Examination was
performed using light microscopy at a magnification of 3100.
Quantitative evaluation of connective tissue staining
Connective tissue was quantified in five randomly chosen
animals per group using a score for the amount of Sirius
staining in the intima, media and adventitia of the aortic
wall. The grading was as follows: 0, no staining; 1, little
staining; 2, moderate staining; 3, widespread staining.
Statistics
Data are given as means"SD. Statistical analysis was per-
formed using one-way ANOVA followed by Bonferroni–Dunn
multiple range test.
Table 1. Systolic BP (mmHg, measured by tail plethysmography) in the last week of the experiments (week 8)
Groups WKY
sham
WKY
iso
WKY
allo
WKY
alloq
ACEi
WKY
alloq
ETARB
WKY
alloq
comb
SHR
sham
SHR
iso
SHR
allo
SHR
alloq
ACEi
SHR
alloq
ETARB
SHR
alloq
comb
Systolic
BP
120"20 100"13 111"17 103"19 118"17 108"9 166"31* 144"20* 159"24* 113"21y 149"15z 128"14y
WKY, Wistar–Kyoto rats; SHR, spontaneously hypertensive rats; sham, sham-operation; iso, isotransplantation; allo, allotransplantation;
ACEi, ACE inhibitor; ETARB, ETA-receptor blocker; comb, combination therapy (ACEiqETARB). *P-0.001 vs WKY sham, iso and all
allo groups; yP-0.01 vs SHR allo; zP-0.001 vs SHR allo treated with ACEi monotherapy.
Fig. 1. Aortic wall thickness (mm) in WKY (A) and SHR rats (B). Sham, sham-operation; iso, isotransplantation; ACEi, ACE inhibitor;
ETARB, ETA-receptor blocker; comb, combination therapy (ACEiqETRB). *P-0.01 vs treatment groups; yP-0.01 vs allograft groups.
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Results
Animal data
Body weight and blood parameters. Body weight, hae-
maglobin, haematocrit, serum creatinine, serum urea,
electrolytes, serum cholesterol and triglycerides did
not differ between the groups in both experimental
settings (data not shown).
Blood pressure. Sham-operated, iso- and allotran-
splanted SHRs had higher systolic BP than the res-
pective WKY rats (P-0.001). Systolic BP was not
altered in either strain after iso- and allotransplanta-
tion had been performed. Trandolapril, but not LU,
significantly reduced systolic BP in allotransplanted
SHRs. Combination treatment with trandolapril plus
LU did not further decrease systolic BP in SHRs as
compared with trandolapril alone. In normotensive
WKY neither of the treatments influenced systolic
BP (Table 1).
Morphological studies
Morphology in isografts was virtually normal and was
comparable with that of sham-operated rats in either
experimental setting, i.e. SHR-to-WKY and WKY-to-
SHR grafts. In sham-operated animals, aortic wall
thickness was not different between SHR and WKY
(Figure 1). Aortic wall thickness was significantly
greater, however, in SHR recipients of WKY allografts
as compared with WKY recipients of SHR allografts
(Figures 1 and 3). LU attenuated the increase in
wall thickness in both rat strains (Figures 1 and 2).
Fig. 2. Aortic wall thickness in sham-operated (A) and iso-transplanted (B) WKY animals as negative controls compared with untreated
allotransplanted WKY (C), allotransplanted WKY treated with the ACE inhibitor trandolapril (D), the ETA-receptor blocker LU 302146 (E),
and a combination of ACE inhibitor and ETA-receptor blocker (F), respectively. Semithin sections, magnification 3100.
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This effect was due to attenuation of the increase in
media and intima thickening. The magnitude of the
effect of ETA-receptor blockade was comparable with
that of ACE inhibition. There was no statistically
significant difference between combination therapy
and the respective monotherapies (Figures 1 and 2).
These data were confirmed by measurement of the
cross-sectional aortic areas and the wall:lumen ratio
(data not shown).
Connective-tissue staining
Connective-tissue staining in the aortic wall was more
pronounced in untreated allotransplanted animals when
compared with sham-operated or isotransplanted ani-
mals of either strain. This increase in the amount of
connective tissue was similarly reduced by ACE
inhibition, ETA-receptor blockade and combination
therapy (Table 2).
Immunohistochemistry
Proliferating cell nuclear antigen. The number of
PCNA-positive cells per intima and media cross sec-
tion was significantly higher in untreated allotrans-
planted animals compared with sham-operated or
isotransplanted animals in both strains. The PCNA
staining was comparable in sham-operated and iso-
transplanted rats. Treatment with LU and trandola-
pril was similarly effective in attenuating the increase
in the number of PCNA-positive cells in the
intima. In the media, the effect of trandolapril was
significantly more pronounced than that of LU.
Combination treatment did not confer additional
benefit. The results of PCNA immunohistochemistry
are shown in Figure 4.
Transforming growth factor-b. Immunostaining for
TGF-b was virtually negative in sham-operated and
isografted animals of both strains. In contrast, TGF-b
staining was strongly detectable in allotransplanted
WKY and SHR animals. This increase in TGF-b
staining was markedly abrogated by treatment with
trandolapril, but not by treatment with LU. Com-
bination therapy did not confer an additional benefit
compared with ACE inhibition alone (Figure 5).
Discussion
The present study documents that development of
chronic transplant vasculopathy in two different aorta
allotransplantation models is abrogated to a similar
extent by treatment with the ETA-receptor blocker LU
and the ACE inhibitor trandolapril. This result
confirms that the beneficial effect of ETA-receptor
blockade is not unique to the kidney, i.e. the ‘Fisher-
to-Lewis’ chronic transplant nephropathy model [5],
and points to a more general role of the ET system in
chronic allograft rejection.
The normotensive (aortic allotransplantation from
SHR-to-WKY) and hypertensive (aortic allotransplan-
tation from WKY-to-SHR) models used in our study
Fig. 3. Iso-transplanted aortic graft thickness in SHR (A) compared with marked thickening of aortic wall in untreated allotransplanted
SHR (B). Semithin sections, magnification 3140.
Table 2. Results of the quantitative evaluation of Sirius-staining for connective tissue in the intima, media and adventitia of the aortic wall
(given as a score as described in Subjects and methods)
Groups WKY
sham
WKY
iso
WKY
allo
WKY
alloq
ACEi
WKY
alloq
ETARB
WKY
alloq
comb
SHR
sham
SHR
iso
SHR
allo
SHR
alloq
ACEi
SHR
alloq
ETARB
SHR
alloq
comb
Intima 0"0 0"0 2"0a 1.2"0.45b,c 1"0b 0.6"0.55b 0"0 0"0 2.4"0.55a 2"0a 1.6"0.55b 1.4"0.55b
Media 1.2"0.45 1"0 2.2"0.45a 1.2"0.45d 1"0d 1"0d 1.2"0.45 1"0 2.4"0.55a 1.4"0.55d 1"0d 1"0d
Adventitia 2"0 1.2"0.45e 3"0e,f 2"0f,d 1.6"0.55d 1.4"0.55d 2"0 1"0e 2.8"0.45e,f 2"0f,d 1.6"0.55d 1.8"0.45d,g
Sham, sham-operation; iso, isotransplantation; allo, allotransplantation; ACEi, ACE inhibitor; ETARB, ETA-receptor blocker; comb,
combination therapy (ACEiqETARB). aP-0.001 vs sham and iso; bP-0.05 vs sham, iso and allo; cP-0.05 vs alloqcomb; dP-0.05 vs allo;
eP-0.05 vs sham; fP-0.05 vs iso; gP-0.05 vs iso.
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are accepted standard models of chronic transplant
vasculopathy [9]. Plissonnier et al. [10] reported that
ACE inhibition is beneficial in these models. Therefore,
we used the ACE inhibitor trandolapril as a positive
treatment control. Interestingly, LU, in contrast to
trandolapril, did not lower BP in the hypertensive
model of WKY-to-SHR aorta transplantation, but it
was nevertheless equally protective. On the other hand,
both ACE inhibitor and ETA-receptor blocker abro-
gated transplant vasculopathy in the normotensive
model of SHR-to-WKY aorta transplantation despite
no BP lowering.
The effect of LU must be interpreted to indicate that
(i) ET plays a crucial role in progression of chronic
transplant vasculopathy and (ii) that the effects of ETs
are, at least partly, mediated via the ETA receptor. The
combination therapy of ACE inhibitor and ETA-
receptor blocker did not confer additive benefit on
the parameters investigated. This finding is compatible
with the idea that ACE inhibition and ETA-receptor
blockade share, at least in part, similar pathogenetic
pathways. One possibility may be the reduction of ET-1
synthesis by ACE inhibition [11]. Another possibility
may be that the undoubtedly present differences in
the mechanisms of action of both drugs are equally
effective in attenuating chronic transplant vasculo-
pathy. Due to these differences one would have expected
that combination therapy exerts an additive benefit.
The lack of such an additive effect remains unclear, but
it parallels the finding in the ‘Fisher-to-Lewis’ chronic
allograft nephropathy model [5]. BP in SHRs was not
lowered more by combination therapy than by ACE
inhibition alone. This observation is of note, because
some studies had reported that combination of
angiotensin II receptor blockers with ETA-receptor
blockers had an additive hypotensive effect [12]. The
lack of such an effect in our study may be due to the
different animal models used, and the use of ACE
inhibitors instead of angiotensin II receptor blockers.
Our experiment does not specifically exclude effects
of ETA-receptor blockade on immune recognition or
effector steps in the allograft. There is a body of
evidence, however, that ET-1 amplifies immune and
non-immune effector mechanisms in chronic allograft
rejection. The latter appears plausible in view of the
known actions of ET-1 on vascular smooth muscle
cells (VSMC). Transplant vasculopathy, the hallmark
of chronic rejection, is characterized by endothelial cell
damage and VSMC proliferation and migration. ET-1
is a potent mitogen for VSMC and mesangial cells [13],
and the mitogenic effect of ET-1 is mediated via the
ETA-receptor [14].
Suppression of cell proliferation by ACE inhibition
and ETA-receptor blockade as a major beneficial
mechanism is implicated by the results of our
immunohistochemical studies. Treatment with either
agent inhibited the increase in number of PCNA-
positive cells in the media and intima of aorta
allografts. Although PCNA is not an absolute spe-
cific marker of proliferation, this indicates attenuation
of proliferative activity of aortic wall cells. As far
Fig. 4. PCNA-positive cells in the intima (A) and media (B) of sham-
operated (sham), isotransplanted (iso), and allotransplanted (allo) WKY
rats and SHR rats ((C) intima and (D) media), respectively.
Allotransplanted rats of bothstrains were treated witheither trandolapril
(ACEi) or LU 302146 (ETARB), or a combination of both. *P-0.001 vs
all groups; yP-0.001 vs iso; zP-0.05 vs alloqACEi; §P-0.01 vs sham;
IP-0.05 vs iso; }P-0.01 vs alloqcombination; #P-0.001 vs alloq
ETARB; **P-0.001 vs iso and sham;
yyP-0.05 vs allo.
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as the media is concerned, ACE inhibition appears to
be more effective than ETA-receptor blockade con-
cerning this parameter. The reasons for this difference
remain to be elucidated.
Interestingly, the expression of TGF-b was abro-
gated by ACE inhibition and combination therapy, but
not by monotherapy with the ETA-receptor blocker.
This effect was particularly pronounced in the neo-
intima. Overexpression of TGF-b is a known feature of
chronic rejection in humans and animal models [11,15].
Abrogation of TGF-b immunostaining by ACE inhi-
bition was also reported in the ‘Fisher-to-Lewis’ renal
allograft model of chronic rejection [16]. TGF-b may
be a player in chronic allograft vasculopathy because it
is a strong growth factor promoting hypertrophy and
extracellular matrix production of several cell types,
e.g. VSMC [17]. Attenuation of TGF-b expression by
trandolapril is plausible due to activation of TGF-b by
angiotensin II [18]. This indicates that the protective
effect of trandolapril may be partially mediated by
inhibition of TGF-b. On the other hand, the negative
result of ETA-receptor blockade on TGF-b immuno-
staining implies that the protective effect of LU is
mediated via a different mechanism. TGF-b is also
activated by ET-1, but the production of the latter is
not affected by ETA-receptor blockade [18], which may
explain the negative result with LU. The lack of effect
of LU on these parameters suggests other mechanisms
of its beneficial effect on aortic graft thickening. One
explanation may be that ETA-receptor blockade sup-
presses the effect of other growth factors, such as
platelet-derived growth factor [19] or epidermal growth
factor [20]. Similarly to our results, Kelly et al. [18]
reported that in the transgenic (mRen-2)27 rat, TGF-b
Fig. 5. TGF-b immunostaining in the different groups of SHR rats: sham-operated (A) and iso-transplanted (B) SHR animals as negative
controls compared with untreated allotransplanted SHR (C), allotransplanted SHR treated with the ACE inhibitor trandolapril (D), the ETA-
receptor blocker LU 302146 (E), and a combination of ACE inhibitor and ETA-receptor blocker (F), respectively. Magnification 3140.
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overexpression was not affected by the mixed ETAu
ETB-receptor blocker bosentan, but by the angiotensin
II receptor blocker valsartan.
We emphasize that we controlled several potential
confounders. Specifically, sodium intake was similar in
all groups and immunosupppressive treatment, i.e.
cyclosporin A, was not used in the present study. This
is of note, because cyclosporin A: (i) interacts with
endothelial cell function; (ii) increases ET secretion
from endothelial cells and VSMC; (iii) elevates ET
plasma level; (iv) modulates ET-receptor expression;
and (v) causes vasoconstriction.
Simonson et al. [4] reported increased immunoreac-
tive ET-1 levels in the vasculature of chronic rejecting
renal allografts in humans. This parallels earlier
findings in coronary artery disease after heart trans-
plantation: Ravalli et al. [3] documented increased ET-1
immunoreactivity in myointimal cells, macrophages
and endothelial cells. Tanabe et al. [21] reported that
endothelin-converting enzyme (ECE) is increased in
arteries of human renal allografts with chronic
transplant nephropathy, suggesting that ET-1 is
generated from big ET-1 by ECE. Inhibition of
ECE with phosphoramidon in a rat model of chronic
cardiac allograft rejection attenuates transplant vasculo-
pathy and rejection [22]. A preliminary report in an
aorta allotransplantation model in the mouse docu-
mented abrogation of chronic transplant vasculopathy
[23]. These findings together with the present study
document that ET-1 plays a major role in the genesis
of chronic rejection of different organs both in animals
and humans. Thus, treatment of chronic rejection with
specific ETA-receptor blockers opens a new perspective.
In view of species differences of the vascular ET
system, it is unknown whether the strikingly beneficial
effects of selective ETA-receptor blockade in the above
aorta allotransplantation models can be extrapolated
to humans. This question can only be addressed by
prospective clinical trials.
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